A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

Publication date: Available online 15 June 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Maryann Kaler, Amisha V. Barochia, Nargues A. Weir, Rosemarie A. Cuento, Mario Stylianou, Mark J. Roth, Armando C. Filie, Ellen C. Vaughey, Steven D. Nathan, Stewart J. Levine
The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma.



http://ift.tt/2tu6xGq